Shared CD8+ T Cell Clones Link Skin and Joint Inflammation in Psoriatic Arthritis

The connection between skin and joint inflammation in psoriatic arthritis (PsA) has long been recognized clinically, but the precise immunological mechanisms bridging these two domains remain incompletely understood. It is unclear what initiates chronic inflammation in PsA and whether the immune mechanisms underlying skin and joint inflammation are identical.

A study published in Arthritis & Rheumatology provides new insights by directly comparing the gene signatures, T cell receptor (TCR) repertoires, and cellular neighborhoods of T cells from paired skin and synovial samples.

Evidence of Antigen-Driven Activation

In this study, investigators utilized single-cell RNA sequencing and spatial transcriptomics to analyze samples from 6 patients with active PsA. The analysis revealed that epidermal CD8+ tissue-resident memory T (Trm) cells co-localize with macrophages and Langerhans cells. This spatial relationship, along with potential ligand-receptor interactions, strongly supports an antigen-driven activation of CD8+ Trm cells originating in the skin.

Shared Clones and Cytotoxic Signatures

A critical discovery was the identification of 155 shared CD8+ T cell clones between the skin and joint. Because it is highly unlikely that independent T cell precursors would rearrange their TCR into the exact same sequence, these shared clones almost certainly descend from the same parent cell. Despite overall differences in the gene signatures of CD8+ T cells between the two sites, these skin-joint shared clones exhibited similar profiles characterized by increased expression of cytotoxicity-associated genes, including GZMB, GNLY, and PRF1.

This clonal sharing suggests that the same antigen is present in both sites, or that T cells migrate between the skin and joint to propagate inflammation. The data indicate that biomechanical injury to a joint might nonspecifically recruit circulating ex-skin Trm cells, which then take up residence and drive PsA development. Furthermore, the study identified shared clones among CD4+ Trm and regulatory T cells, adding weight to the concept of cross-tissue migration.

The IL-17 Disconnect and Novel Targets

The researchers found a stronger interleukin-17 (IL-17) signature in skin CD8+ T cells compared to those from the joint. This molecular finding correlates with real-world clinical experience: IL-17 inhibition typically produces a more profound improvement in psoriatic skin plaques than in joint inflammation. While IL-17 may be a dominant driver in the skin, the presence of GZMK+ cytotoxic Trm cells enriched in the joints suggests other factors contribute significantly to synovial inflammation. Consequently, treating refractory PsA may require combination therapies targeting multiple cytokines or entirely novel targets like GZMK, which has also been implicated in other inflammatory diseases.

A Framework for Further Study

While these findings offer a framework for understanding PsA pathogenesis, the study enrolled only 6 patients with varying disease durations and treatments. Larger cohorts are needed to confirm generalizability. Additionally, further research must investigate the functional impact of the identified ligand-receptor interactions and the precise role of GZMK in driving joint inflammation, keeping in mind that other immune and stromal cells also contribute to the disease.

Translating Pathophysiology to Practice

The demonstration that skin and joint inflammation in PsA is linked through phenotypically similar, migrating T cell clones opens new translational avenues. By deepening our understanding of these antigen-specific interactions, future therapeutic strategies could potentially leverage antigen-specific immunotherapy to induce long-term tolerance in patients with PsA.

Reference:

Durham LE, Humby F, Ng N, et al. Linking Skin and Joint Inflammation in Psoriatic Arthritis through Shared CD8+ T Cell Clones. Arthritis Rheumatol. 2026;78(1):152-165. doi:10.1002/art.43286